# US 2015/0147383 A1 · Method and composition for treatment of dyslipidemia and other diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0147383 A1
- Document ID: US20150147383A1
- Status: Published application
- Kind: A1
- Application number: 14/492,060
- Filed: 2014-09-21
- Published: 2015-05-28
- Earliest claimed: 2013-09-23
- Inventors: Amirhossein Sahebkar; Ali Badiee; Mahmoud Reza Jaafari
- Web page: https://patentgrep.com/patent/US20150147383A1

## CPC

- A61K 47/6913: {the liposome being modified on its surface by an antibody}
- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Anionic liposomes and apolipoprotein B-100 targeted immunoliposomes as therapeutic agents for dyslipidemia and related diseases, and compositions and methods for preparing same.

## Claims

### Claim at position 1

1-36. (canceled)

### Claim 37

A liposomal composition as a therapeutic agent for treating dyslipidemia comprising:
at least one anionic phospholipid; and
at least one neutral phospholipid.

### Claim 38 (depends on 37)

The liposomal composition according to claim 37, wherein said liposomal composition has an average diameter of about 90-150 nanometers.

### Claim 39 (depends on 37)

The liposomal composition according to claim 37, wherein said liposomal composition is substantially cholesterol-free.

### Claim 40 (depends on 37)

The liposomal composition according to claim 37, wherein said liposomal composition does not employ a cationic phospholipid.

### Claim 41 (depends on 37)

The liposomal composition according to claim 37, wherein said at least one anionic phospholipid is selected from the group consisting of Phosphatidylcholine (EPG), Distearoyl Phosphatidylglycerol (DSPG) and combinations thereof.

### Claim 42 (depends on 37)

The liposomal composition according to claim 37, wherein said at least one anionic phospholipid comprises from about 50 to about 90 weight percent of said liposomal composition.

### Claim 43 (depends on 42)

The liposomal composition according to claim 42, wherein said at least one anionic phospholipid comprises from about 65 to about 85 weight percent of said liposomal composition.

### Claim 44 (depends on 37)

The liposomal composition according to claim 37, wherein said at least one neutral phospholipid is selected from the group consisting of Hydrogenated Soy Phosphatidylcholine (HSPC), Soy Phosphatidylcholine (SPC) and combinations thereof.

### Claim 45 (depends on 37)

The liposomal composition according to claim 37, wherein said at least one anionic phospholipid is Phosphatidylcholine (EPG), and wherein said at least one neutral phospholipid is Soy Phosphatidylcholine (SPC).

### Claim 46 (depends on 45)

The liposomal composition according to claim 45, wherein the ratio of SPC to EPG in said liposomal composition is about 1:3.

### Claim 47 (depends on 37)

The liposomal composition according to claim 37, wherein said at least one anionic phospholipid is Distearoyl Phosphatidylglycerol (DSPG), and wherein said at least one neutral phospholipid is Hydrogenated Soy Phosphatidylcholine (HSPC).

### Claim 48 (depends on 47)

The liposomal composition according to claim 47, wherein the ratio of HSPC to DSPG in said liposomal composition is about 1:3.

### Claim 49 (depends on 37)

The liposomal composition according to claim 37, further comprising:
an antibody conjugated within said liposomal composition.

### Claim 50 (depends on 49)

The liposomal composition according to claim 49, wherein said antibody comprises an Apolipoprotein antibody.

### Claim 51 (depends on 50)

The liposomal composition according to claim 50, wherein said Apolipoprotein antibody comprises an Apolipoprotein B 100 antibody.

### Claim 52

A targeted liposomal composition for treating dyslipidemia comprising:
at least one anionic phospholipid;
at least one neutral phospholipid; and
at least one antibody, wherein said antibody is conjugated within said liposomal composition, whereby said targeted liposomal composition is formed.

### Claim 53 (depends on 52)

The liposomal composition according to claim 52, wherein said targeted liposomal composition has an average diameter of about 90-150 nanometers.

### Claim 54 (depends on 52)

The liposomal composition according to claim 52, wherein said targeted liposomal composition is substantially cholesterol-free.

### Claim 55 (depends on 52)

The liposomal composition according to claim 52, wherein said targeted liposomal composition does not employ a cationic phospholipid.

### Claim 56 (depends on 52)

The liposomal composition according to claim 52, wherein said at least one anionic phospholipid is selected from the group consisting of Phosphatidylcholine (EPG), Distearoyl Phosphatidylglycerol (DSPG) and combinations thereof.

### Claim 57 (depends on 52)

The liposomal composition according to claim 52, wherein said at least one anionic phospholipid comprises from about 50 to about 90 weight percent of said targeted liposomal composition.

### Claim 58 (depends on 57)

The liposomal composition according to claim 57, wherein said at least one anionic phospholipid comprises from about 65 to about 85 weight percent of said targeted liposomal composition.

### Claim 59 (depends on 52)

The liposomal composition according to claim 52, wherein said at least one neutral phospholipid is selected from the group consisting of Hydrogenated Soy Phosphatidylcholine (HSPC), Soy Phosphatidylcholine (SPC) and combinations thereof.

### Claim 60 (depends on 52)

The liposomal composition according to claim 52, wherein said at least one anionic phospholipid is Phosphatidylcholine (EPG), and wherein said at least one neutral phospholipid is Soy Phosphatidylcholine (SPC).

### Claim 61 (depends on 60)

The liposomal composition according to claim 60, wherein the ratio of SPC to EPG in said liposomal composition is about 1:3.

### Claim 62 (depends on 52)

The liposomal composition according to claim 52, wherein said at least one anionic phospholipid is Distearoyl Phosphatidylglycerol (DSPG), and wherein said at least one neutral phospholipid is Hydrogenated Soy Phosphatidylcholine (HSPC).

### Claim 63 (depends on 62)

The liposomal composition according to claim 62, wherein the ratio of HSPC to DSPG in said liposomal composition is about 1:3.

### Claim 64 (depends on 52)

The liposomal composition according to claim 52, wherein said at least one antibody comprises an Apolipoprotein antibody.

### Claim 65 (depends on 64)

The liposomal composition according to claim 64, wherein said Apolipoprotein antibody comprises an Apolipoprotein B 100 antibody.

### Claim 66

A method for preparing a targeted liposomal composition for treating dyslipidemia comprising:
preparing a nanoliposome; and
conjugating an antibody to the prepared nanoliposome.

### Claim 67 (depends on 66)

The method according to claim 66, wherein said step of conjugating comprises:
mixing a monoclonal with a reagent, and incubating the admixture, thereby preparing a pyridyldithiopropionated immunoglobulin (PDP-IgG);
separating said PDP-IgG from excess reagent;
preparing, from the admixture after the separation, a thiolated-IgG (IgG-SH) admixture;
preparing and admixing micelle-IgG complexes with said thiolated-IgG admixture, forming a micelle-IgG complex thereof; and
admixing said micelle-IgG complex with liposomes.

### Claim 68 (depends on 67)

The method according to claim 67, wherein said monoclonal is an Apolipoprotein monoclonal.

### Claim 69 (depends on 68)

The method according to claim 68, wherein said Apolipoprotein monoclonal comprises an Apolipoprotein B 100 monoclonal.

### Claim 70 (depends on 67)

The method according to claim 67, wherein the mixing ratio of said micelle-IgG complexes to the liposome is from about 1:2000 to about 1-500.

### Claim 71 (depends on 70)

The method according to claim 70, wherein the mixing ratio of said micelle-IgG complexes to the liposome is about 1:1000.
